Skip to main content

Table 2 Impact of patient characteristics and comorbidities on the continuation of treatment with tadalafil 5 mg OaD (N = 778)

From: Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities

Population Number of patients with Patients without events (%), KM estimate [95 % CI]
  Data Events Month 2 Month 4 Month 6
Overall (primary analysis) 773 107 94.0 [92.3,95.7] 88.3 [85.9,90.6] 86.3 [83.7,88.9]
By age     
 Age ≤65 years 593 61 96.2 [94.7,97.8] 91.7 [89.4,93.9] 89.8 [87.1,92.4]
 Age >65 years 180 46 86.7 [81.7,91.6] 77.3 [71.1,83.5] 75.0 [68.5, 81.5]
By PDE5-I treatment     
 PDE5-I naïve 507 71 93.9 [91.8,96.0] 88.5 [85.7,91.4] 86.1 [82.9,89.4]
 PDE5-I pretreated 265 36 94.2 [91.4,97.1] 87.6 [83.6,91.7] 86.6 [82.3,90.9]
By disease severity     
 Mild ED 160 16 98.1 [96.0,1.00] 94.1 [90.3,97.8] 89.8 [84.4,95.3]
 Moderate ED 407 55 94.8 [92.7,97.0] 88.6 [85.5,91.8] 87.3 [83.9,90.8]
 Severe ED 203 36 89.0 [84.6,93.3] 82.8 [77.4,88.2] 80.8 [75.1,86.5]
By presence of BPH     
 BPH present 49 10 91.8 [84.2,99.5] 87.8 [78.6,96.9] 84.9 [74.5,95.3]
 BPH absent 724 97 94.1 [92.4,95.9] 88.3 [85.9,90.7] 86.4 [83.7,89.1]
By presence of diabetes     
 Diabetes present 123 19 93.4 [88.9,97.8] 85.3 [78.9,91.8] 84.0 [77.2,90.9]
 Diabetes absent 650 88 94.1 [92.3,95.9] 88.8 [86.3,91.3] 86.7 [83.9, 89.5]
By presence of CVD     
 CVD present 266 41 90.9 [87.4,94.4] 86.8 [82.7,91.0] 84.6 [80.1,89.2]
 CVD absent 507 66 95.6 [93.8,97.4] 89.0 [86.2,91.8] 87.2 [84.0,90.3]
By presence of hypertension     
 Hypertension present 258 40 91.0 [87.5,94.5] 86.8 [82.6,91.0] 84.6 [79.9,89.2]
 Hypertension absent 515 67 95.5 [93.7,97.3] 89.0 [86.2,91.8] 87.2 [84.0,90.3]
By presence of dyslipidemia     
 Dyslipidemia present 144 24 91.6 [87.0,96.1] 86.3 [80.6,92.1] 83.5 [77.2,89.9]
 Dyslipidemia absent 629 83 94.5 [92.8,96.3] 88.7 [86.2,91.2] 87.0 [84.2,89.8]
  1. Event = Discontinuation of tadalafil OaD
  2. Note: KM estimates for subgroups with non-overlapping CIs at given time points are marked in bold
  3. BPH benign prostatic hyperplasia, CI confidence interval, CVD cardiovascular diseases, ED erectile dysfunction, KM Kaplan-Meier, N number of patients, OaD once a day, PDE5-I phosphodiesterase type 5 inhibitor